Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.

ABSTRACT: A program to identify novel intravenous sedatives with a short and predictable duration of action was initiated in the late 1990's by Glaxo Wellcome. The program focussed on the identification of ester-based benzodiazepine derivatives that are rapidly broken down by esterases. Remimazolam was identified as one of the lead compounds. The project at Glaxo was shelved for strategic reasons at the late lead optimization stage. Via the GSK ventures initiative, the program was acquired by the small biotechnology company, TheraSci, and, through successive acquisitions, developed as the besylate salt at CeNeS and PAION. The development of remimazolam besylate has been slow by industry standards, primarily because of the resource limitations of these small companies. It has, however, recently been

SUBMITTER: Kilpatrick GJ 

PROVIDER: S-EPMC8329483 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature